EN DE

Alibaba Health Information Technology Limited (0241) Fair Value & Analysis

Healthcare · HK · Market cap HK$49.7B

AH Alibaba Health Information Technology Limited 0241 · HK
PriceHK$3.66
Fair ValueHK$2.04
Upside-44.3%
Quality64/100
Watch Alibaba Health Information Technology Limited for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 5.7% net margin
Low debt · generates free cash flow
Mixed vs. peers (6/13)
Moderate moat 45/100
Evidence: High Range HK$1.55 – HK$2.55 Share as image

Fair value as of: Aug 2, 2026

From 26 valuation models · updated 8 days ago

Share price +5.5% over the past month.

A solid business, but screening 44% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$2.55). The favourable scenario is already priced in.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$24.55 HK$2.61 Fair Value HK$2.04 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.

How to read this chart

60‑month range HK$2.61 – HK$24.55 · fair‑value band HK$1.55 – HK$2.55 · the HK$3.66 price screens above the HK$2.04 fair value. Dashed = 300-day average. As of Aug 2, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Alibaba Health Information Technology Limited (0241) currently trades at HK$3.66, while our model-based Fair Value estimate is HK$2.04, implying the stock looks roughly 44.3% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Alibaba Health Information Technology Limited generated revenue of HK$34.3B at a net margin of 5.7%. Revenue grew 7.6% year over year. It earns a return on equity of 11.3%. The balance sheet holds a net cash position of HK$5.7B. Fundamentals as of Aug 2, 2026

Our scenario range runs from HK$1.55 (bear case) to HK$2.55 (bull case); at HK$3.66, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -44%, 0241 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$1.71 HK$3.04 HK$5.22 80
Residual Income HK$0.9900 HK$1.13 HK$2.11 76
Rev-Margin DCF HK$1.72 HK$2.82 HK$5.14 74
All 26 models by family
DCF Models
FCF DCF HK$1.79 HK$2.62 HK$5.24 38
Owner Earnings HK$2.28 HK$4.73 HK$9.88 31
5Y Revenue Exit HK$1.59 HK$2.51 HK$4.46 39
5Y EBITDA Exit HK$1.68 HK$2.70 HK$4.71 41
5Y P/E Exit HK$2.25 HK$4.74 HK$8.16 38
10Y Revenue Exit HK$1.62 HK$3.20 HK$4.22 36
10Y EBITDA Exit HK$1.74 HK$3.40 HK$6.28 37
10Y P/E Exit HK$2.15 HK$4.62 HK$8.73 35
Earnings-Based
Graham-Dodd HK$0.8200 HK$5.69 HK$7.99 54
Lynch FV HK$2.94 HK$4.20 HK$5.46 50
PEG = 1.0 HK$2.94 HK$4.20 HK$5.46 46
EPV HK$1.24 HK$1.39 HK$1.52 59
Dividend Discount
Gordon GGM HK$0.3700 HK$0.7700 HK$1.21 70
DDM Multi-Stage HK$0.3700 HK$0.6500 HK$0.8000 61
Multiples
P/E Multiple HK$1.98 HK$2.64 HK$3.30 63
P/S Multiple HK$1.53 HK$2.04 HK$2.55 58
P/B Multiple HK$1.53 HK$2.04 HK$2.55 55
EV/EBIT HK$1.81 HK$2.29 HK$2.78 53
EV/EBITDA HK$1.59 HK$2.00 HK$2.41 54
EV/Revenue HK$1.39 HK$1.84 HK$2.28 43
Asset-Based
NCAV (Graham) HK$0.5500 HK$0.7400 HK$1.10 50
Growth DCF
Growth DCF HK$1.71 HK$3.04 HK$5.22 80
Rev-Margin DCF HK$1.72 HK$2.82 HK$5.14 74
Economic Profit
Residual Income HK$0.9900 HK$1.13 HK$2.11 76
ROIC Compounder HK$1.42 HK$1.85 HK$2.26 72
Growth Earnings
Growth-Adj P/E HK$3.91 HK$5.58 HK$7.25 68

Widest divergence: Growth Earnings (HK$5.58) versus Dividend Discount (HK$0.6500). Highest evidence: Growth DCF (80).

Notify me when 0241 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$34.3B
Revenue growth (YoY) +7.6%
Net margin 5.7%
Return on equity 11.3%
Free cash flow HK$1.4B FY2025
P/E ratio 22.0
More key figures
Operating margin 1.7%
EPS (TTM) HK$0.1200
EPS growth (YoY) +0.7%
Net cash HK$5.7B FY2026

Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 64 · Market factors (momentum, volatility) 14

Profitability 60
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 43
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 24
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 47
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong.

Full company description

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Alibaba Health Information Technology Limited reported revenue of HK$34.3B in FY2026 versus HK$20.6B in FY2022, a compound +13.6%/yr. Reported net income was HK$1.9B in FY2026.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2026)
HK$34.3B
Latest YoY
+12.0%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.6%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+17.2%
Avg. growth/yr (26Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+33.4%
Revenue +13.6%/yr
FY22 HK$20.6B
FY23 HK$26.8B
FY24 HK$27.0B
FY25 HK$30.6B
FY26 HK$34.3B
Net income
FY22 −HK$266M
FY23 HK$536M
FY24 HK$883M
FY25 HK$1.4B
FY26 HK$1.9B

0241 screens 44% overvalued. Compare with JD Health International Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alibaba Health Information Technology Limited · Fair Value
HK$2.04 −44%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Alibaba Health Information Technology Limited Fair Value". https://www.fairvalue-calculator.com/stock/0241

Peer Group

Pharmaceutical Retailers · 61 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −44% · Below median
Return on equity (TTM) 11% · Above median
Return on assets 4% · Above median
Net margin (TTM) 6% · Top 25%
Operating margin (TTM) 2% · Below median
Revenue growth 8% · Above median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 22.0× · Pricier than median
P/B 2.79× · Pricier than median
P/S (TTM) 1.45× · Pricier than 75% of peers
P/FCF 4.6× · Pricier than 75% of peers
EV/EBITDA 30.4× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 19
FUTURE 38 · sector 19
PAST 45 · sector 19
HEALTH 100 · sector 97
DIVIDEND 0 · sector 66

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$39.20 HK$33.28 -15%
Raia Drogasil S.A RADL3 R$18.20 R$15.58 -14%
Yifeng Pharmacy Chain Co 603939 ¥20.24 ¥29.07 +44%
DaShenLin Pharmaceutical Group 603233 ¥17.81 ¥23.86 +34%
Corporativo Fragua, S.A. FRAGUAB 463.00 MXN 821.18 MXN +77%
LBX Pharmacy Chain Joint Stock Company 603883 ¥11.51 ¥10.57 -8%
MedPlus Health Services Limited MEDPLUS ₹690.20 ₹379.25 -45%
Yixintang Pharmaceutical Group 002727 ¥11.46 ¥9.45 -18%
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.40 ¥10.05 -30%
Apotea AB APOTEA kr 74.75 kr 43.95 -41%

Compare Alibaba Health Information Technology Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Alibaba Health Information Technology Limited (0241) overvalued or undervalued?
As of Aug 2, 2026, our model estimates a fair value of HK$2.04 versus a price of HK$3.66, about −44% (overvalued).
What is the fair value of 0241?
Our model-based fair value for Alibaba Health Information Technology Limited is HK$2.04 (as of Aug 2, 2026), built from audited fundamentals. The current price is HK$3.66.
What is the quality score of 0241?
Alibaba Health Information Technology Limited has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Alibaba Health Information Technology Limited (0241)?
Alibaba Health Information Technology Limited reported trailing-twelve-month revenue of about HK$34.3B (latest available figure, as of Aug 2, 2026).
What is the net profit margin of 0241?
The net profit margin of Alibaba Health Information Technology Limited is about 5.7%, meaning it keeps roughly 5.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Alibaba Health Information Technology Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.